Background
As confirmed by several randomized clinical trials (RCTs), consensus documents, and meta-analyses, allergen immunotherapy (AIT) has led to crucial changes in clinical outcomes compared to standard treatments in selected patients, as it is the only therapeutic approach able to modify the underlying course of the disease and recover from the disease [1-4].
Despite the presence of robust evidence, very sparse data [5] are available on the efficacy of AIT on selected patients inreal-life , a research method that takes into account realfactors of daily clinical life, and aims to evaluate the true effectiveness of innovative therapies.
With the aim to fill this gap, we performed a pilot, monocenter, retrospective cohort study to evaluate real-life data on efficacy and perceived satisfaction of 3-year sublingual immunotherapy (SLIT), measured by a validated questionnaire, in a population of mono- or poly-sensitized patients with allergic rhinitis and/or asthma.